By Jeremiah Frueauf, Erin Heenan and Matthew Smith ( August 29, 2017, 12:59 PM EDT) -- It's no secret that the U.S. Supreme Court's foray into 35 U.S.C. § 101 has left life sciences and software companies searching for renewed certainty of what is and what is not patent eligible. While the court has seemingly returned to a slumber on issues of § 101, these companies continue to press lower courts, the U.S. Patent and Trademark Office and Congress for solutions. The chances of a legislative solution remain far off, thus these companies must seek guidance through the USPTO and courts....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.